2.520USD-4.91%Mkt Cap: 7.00M USDP/E: —Last update: 2026-05-26
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap7.00M USD
Enterprise Value5.36M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-13.56M USD
Revenue/Share—
Last Price2.520 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees12
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.68
PEG—
EV/EBITDA-0.37
EV/Revenue—
P/S—
P/B2.70
EPS (TTM)-4.07
EPS (Forward)-3.75
52W Range
1.7604% of range19.63
52W High19.63 USD
52W Low1.760 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-243.20%
ROA-173.59%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-11.39M USD
CapEx (TTM)850.00K USD
FCF Margin—
FCF Yield-97.53%
Net Debt-1.69M USD
Net Debt/EBITDA0.12
Balance Sheet
Debt/Equity0.00
Current Ratio0.98
Quick Ratio0.85
Book Value/Sh0.9490 USD
Cash/Share0.6150 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateDec 23, 2019
Splits
Last Split1:25
Split DateDec 17, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.2.75M
Float2.48M
Insiders13.69%
Institutions10.31%
Short Interest
Short Ratio1.8d
Short % Float5.69%
Short % Out.4.94%
Shares Short135.44K
Short (prev mo.)57.55K
Technical
SMA 502.756 (-8.5%)
SMA 2004.573 (-44.9%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)63.09K
Avg Vol (10d)80.42K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—